CAR-T Cancer Fighters in the Real World

From Economy:  NCI T cell attack cancer —  National Cancer Institute \ Duncan Comprehensive Cancer Center at Baylor College of Medicine

From Economy: NCI T cell attack cancer

National Cancer Institute \ Duncan Comprehensive Cancer Center at Baylor College of Medicine

An interesting, detailed article from Alex Lash at Xconomy reviewing the progress of the first two CAR-T therapies approved, Kymriah (from Novartis) and Yescarta (from Gilead Sciences). While the article may seem a bit negative, we think it simply reflects the normal difficulties of introducing a brand new, radically different, medical technology in to a complicated world.

A generation ago, cancer treatments made from a patient’s own living immune cells would have been science fiction. Now they’re here. The first two products, approved in 2017 and known in shorthand as CAR-T, have brought some people with otherwise untreatable blood cancers back from the brink of death.

The experimental results that led to approval for each product were remarkable. But outside the cautious, tightly controlled bubble of clinical studies, the products and their owners have had different experiences in the real world.

Read the full article at Xconomy HERE

Welcome 2019!...(we're not in the office today due to snow and ice...but, still online and doing business)

image from visit albuAlbuquerquequerque (

image from visit albuAlbuquerquequerque (

Hi All,

Nature happens … which is why we built the evo system! Snow and ice combination blew into Albuquerque yesterday (New Year’s Day). The city and Savsu are largely shut down today due to hazardous driving conditions. However, most of us are working on-line so, call and email like normal, and we can all pretend that we are in our offices. (We just aren’t shipping or receiving.)

Weather, customs, strikes, airport issues…there are a million reasons why your critical shipments might be delayed, or potentially delayed (just like today). The evo system keeps your payload thermally safe in these circumstances, lets all parties know exactly where your evo unit is and what the operating conditions are (internal and external), and allows our fantastic, specialty courier partners to show off their stuff (and maybe avoid the delay all together). So, Savsu’s headquarters may be closed today but, just like our evo system, our company is online and doing business.

Local conditions - KOB TV website:

We are moving! (No, we are serious this time.)


(Update: 12/3/2018: We did it!)

Well its about 60 days late but, we are definitely moving in to our new digs this week! What does that mean?

First, our new address is:

4209 Balloon Park Rd. NE Albuquerque, NM 87109

Second, we are physically moving on Thursday and Friday of this week. We will be moving offices, computers, production equipment, inventory and switching over our data network on those days so, we are anticipating some communication issues. If you need to speak with us on Thursday or Friday, email and call and then be a little patient and we will get back to you when we get a signal.

Finally, our ability to ship will be very limited at the end of the week. Call our Customer Service team and let them know what you need this week and what can wait until next week.

We are very, very excited to relocate but, the actual move is going to be a little messy and there will be a few things still to finish after the move. Hang in there!

Looking forward to your visiting the new place.

SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis

avexis logo.png

Very excited to be working with the great folks at Avexis on getting their important gene therapy to market using our evo system. Interesting application in our -80C range. Our patented VialRack technology dramatically improves performance of -80C shippers using a fraction of the dry ice. (-80 evos here).

Read about Avexis and their amazing technology here.

ALBUQUERQUE, N.M., Nov. 5, 2018 /PRNewswire/ -- SAVSU Technologies, a leading developer and supplier of precision cloud-connected thermal shipping containers and the most advanced cold chain visibility platform ("SAVSU"), today announced that it is supplying its evo Smart Shipper and to AveXis, a gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Bruce McCormick, SAVSU President, commented, "We are very pleased to partner with AveXis to supply our best in class evo Smart Shipper and cloud app. We look forward to additional announcements related to adoption of our innovative cold chain technologies by cell and gene therapy companies."

Privately held SAVSU Technologies is driving improved cold chain management of time and temperature cell and gene therapies through innovation and leveraged relationships with the leading specialty couriers serving the regenerative medicine market.  BioLife Solutions (NASDAQ: BLFS), the leading supplier of biopreservation tools for regenerative medicine, holds a 44% equity ownership position in SAVSU.

Full PR Newswire here

See You In Shanghai!

phacilitate shanghai.png

We will be exhibiting at Phacilitate's Advanced Cell Therapy - Shanghai Summit October 29-31 in Shanghai, China.   Massive interest in our evo system in China and across Southeast Asia, and this gives us a chance to meet some of those folks in person.   

Please contact us if you would like to set up a meeting while we are in Shanghai.



NYT: He Got Schizophrenia. He Got Cancer. And Then He Got Cured.

Image: Credit - Jesse Jacobs from NYT September 29, 2018

Image: Credit - Jesse Jacobs from NYT September 29, 2018

Watershed moments occasionally come along in medical history when previously intractable or even deadly conditions suddenly become treatable or preventable. They are sometimes accompanied by a shift in how scientists understand the disorders in question. 

We now seem to have reached such a threshold with certain rare autoimmune diseases of the brain. Not long ago, they could be a death sentence or warrant institutionalization. Now, with aggressive treatment directed at the immune system, patients can recover. Does this group encompass a larger chunk of psychiatric disorders? No one knows the answer yet, but it’s an exciting time to watch the question play out.

Just a fascinating article by Moises Velasquez-Manoff in the New York Times September 29, 2018 about an immune system link to mental health problems. We live in exciting times!

Read the article HERE

Euro Privacy: From TechCrunch - France records big jump in privacy complaints since GDPR


France’s CNIL  agency said today that it’s received 3,767 complaints since May 25, when GDPR came into force, up from 2,294 complaints over the same period last year — which it notes was already a record year.

CNIL says this represents a 64% increase in complaints, which it suggests shows that EU citizens have “seized the GDPR strongly” — attributing public engagement on the issue to media attention on the new regulation and on data protection stories such as the Facebook-Cambridge Analytica data misuse scandal.

It also reports receiving more than 600 data breach notifications, affecting a total of around 15 million people, since GDPR D-Day.

Read the full article at TechCrunch: HERE

Privacy, security, 21 CFR Part 11 compliance are all critical features in the software used in manufacturing of and logistics for cell and gene therapies. We have spent a lot of time and effort making our the best it can be in all these areas. Contact us to talk about our approach to satisfying these important, new, and complicated issues.

See You in La Jolla!


We will be attending Cell and Gene - Meeting On The Mesa in La Jolla, CA again this year.   Meeting is October 3-5.  Great opportunity to meet, talk and learn in a wonderful setting.   Please reach out directly or, using the conference app, if you would like to set aside some time.



Estancia La Jolla Hotel & Spa
9700 North Torrey Pines Road | La Jolla, CA 92037

evo® accepted in to United Cargo's TempControl and LifeGuard system!

united 737.png

Very excited that United Airlines Cargo has accepted our evo® system into their TempControl and LifeGuard services.  The evo system's unique dynamic performance and lean external packaging system open the evo to shipping on both narrow body and wide body aircraft, thus allowing shippers to take full advantage of United's extensive route system.  We look forward to serving United's cargo customers.

- Dana

United Cargo Announces Acceptance of Savsu Technologies evo Cold Chain 2.0 System  


CHICAGO, September 5, 2018– United Cargo today announced it will further enhance both its TempControl and LifeGuard services by accepting the evo®Cold Chain 2.0™ system developed by Savsu Technologies. 

TempControl is United Cargo’s leading service for pharmaceuticals and other health care and life science material requiring temperature-controlled transport, and LifeGuard provides the carrier’s highest-priority same-day service for critically important medical shipments. The evo Cold Chain 2.0 is a fully integrated system designed specifically to provide comprehensive end-to-end transport protection and visibility for live cells used in biotechnology and precision medicine applications.  

“The goal of expanding our customers’ options for packaging and transport systems is to ensure our services remain as relevant and valuable as possible,” said Jan Krems, President United Cargo. “Combining the elevated care and expedited priority of our TempControl and LifeGuard services with the proven thermal stability and dynamic data monitoring and visibilityof the evo Cold Chain 2.0 meets the needs of shippers of the most fragile and precious live material.”

“We are thrilled to participate in United Cargo’s TempControl and LifeGuard programs,” said Bruce McCormick, President Savsu Technologies. “The lean outer packaging of Savsu’s durable, high-performance shipping containers will optimize United’s network for advanced therapy and specialty courier clients by making transport available on both widebody and narrowbody aircraft.” 

United Cargo customers seeking more information on the specifications and availability of the evo Cold Chain 2.0 system should visit




SAVSU is a leading designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals.  Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. For more information please visit


About United Cargo

United Cargo delivers superior shipping solutions via the cargo capacity of the world’s most comprehensive route network – approximately 4,600 flights a day to 357 airports operated by United Airlines and United Express. United operates a mainline fleet of 757 aircraft, including over 170 wide-bodies, on which United Cargo carried over 3 billion cargo ton miles in 2017. With U.S. mainland hubs in Chicago, Denver, Houston, Los Angeles, New York/Newark, San Francisco and Washington, D.C., and enhanced service to and from Asia and Australia, Europe, Latin America and the Middle East, United Cargo quickly transports customers’ shipments to and from virtually every major cargo market in the world. For more information, please visit



Media & Investor Relations

Bruce McCormick


SAVSU Technologies 

2430 Alamo Avenue SE Albuquerque, NM 87106

Savsu Lands New Investment To Fund Accelerating Growth

biolife logo 2.png

Wow, what a busy day!   The first day of Biotech Week - Boston,  great news from United Air Cargo on evo product acceptance into their TempControl and LifeGuard services, and BioLife stepping up to make a big financial investment in Savsu.   We have worked closely with the team at Biolife for years and admire their product, management talent and values.   We appreciate their endorsement of our technology and our team at Savsu.  Most importantly, BioLife's investment allows us to support the accelerating demand for our evo system in cell and gene therapy.

- Dana

Here is the press release issued this morning:

BioLife Solutions Increases Ownership in SAVSU Technologies to 44% with $5 Million Investment

 Agreement Includes 18-Month Option to Acquire all SAVSU Outstanding Shares

BOTHELL, Washington—  September 5, 2018 —BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife”), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that it has increased its ownership of SAVSU Technologiesfrom approximately 31% to 44% with a $5 million investment. SAVSU will use the investment to scale up its operations and inventory to support increased demand for its evo®Dry Vapor Shippers and other precision temperature controlled shipping containers for cell and gene therapies.

The 18-month purchase option provides BioLife, at its sole discretion, with the right to acquire the 56% of SAVSU not already owned, for the greater of 1,000,000 shares of BioLife common stock, or approximately $23 million of BioLife common stock, calculated on the day of exercise.  If BioLife exercises the purchase option in the future, 75% of the shares would be issued at closing, with the remaining 25% issued upon the achievement of specific revenue milestones.

Mike Rice, BioLife CEO, commented, “This additional investment in SAVSU supports our previously announced growth strategy to invest in companies and technologies that also supply the cell and gene therapy industry with innovative, highly valued solutions.  We believe SAVSU is at an inflection point in product adoption in the cell and gene therapy market. The purchase option provides BioLife with complete flexibility with regard to a full acquisition of SAVSU, while setting a value today.  Our decision to exercise the purchase option will be based on SAVSU’s continued revenue growth, and determining the optimal time to consolidate SAVSU and BioLife’s financial results.”

“We welcome this additional investment by BioLife as we grow our business,” stated Dana Barnard, SAVSU Technologies CEO. “SAVSU shippers and our evo cloud-based information system are currently being used by or in final evaluation with over 30 leading cell therapy companies. Along with these direct customers we are working closely with the world’s leading specialty logistics companies to provide seamless global distribution of the SAVSU shippers with real time information systems. SAVSU shippers can be used for both apheresis collections and manufactured cell therapies. Providing both inbound and outbound shipments on a single information platform, integrated with logistics partners and manufacturing sites, is our unique added value in the currently fragmented cold chain logistics paradigm.”

About BioLife Solutions

 BioLife Solutions is the leading developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues. Our proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the regenerative medicine, biobanking and drug discovery markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function.

For more information please visit, and follow BioLife on Twitter.

About SAVSU Technologies

SAVSU is a privately held designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. For more information please visit

 Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, the potential utility of and market for its products and services and potential revenue growth and market expansion. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.



 # # # #





Media & Investor Relations


Roderick de Greef

Chief Financial Officer

(425) 686-6002





See You In London!

phacilitate leaders europe.png

Heading straight to London for Phacilitate: Leaders Europe 2018 following Boston Biotech Week conferences.  Conference is September 11-12.  

Bruce McCormick, President of Savsu, will be speaking on September 11 as part of the program on commercialization .

Please note that for this conference we will have a meeting room rather than a booth in the exhibit hall.  Our room is:  Willow 3  (1 level above the exhibition hall). We will have samples of our evo DV series units on display in the room.

Conference info: (click to go to site)

11-12 SEPTEMBER 2018

FDA Issues New CMC Guidance For Cell & Gene Therapy. Savsu Can Help

fda 3d.png

July 20, 2018, the FDA published this document:

Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)…Draft Guidance for Industry

The FDA Guidance Document Can be found HERE

We finally finished reading the whole thing and wanted to bring your attention to Module 2 (Summary of Quality Information), Section D (Product Handling At The Clinical Site).   Please read the following excerpt from that document and, if you are uncertain how to comply, then call us (or stop by to see us at the upcoming shows in Boston and London).  

Module 2. Summary of Quality Information
Section D. Product Handling at the Clinical Site

Proper control of the finished DP is critical to your investigational studies. Therefore, your IND should also include a description of how the product will be shipped to, received, and handled at the clinical site to ensure safety, product quality, and stability.  Your IND should also include information on shipping conditions, storage conditions, expiration date/time (if applicable), and chain of custody from the manufacturer to the site of administration in the summary information of the CTD. Your summary in Module 2 should also include information for product handling at the clinical site prior to administration (such as thawing, washing, or the addition of diluent or adjuvant, loading into a delivery device, and transport to the bedside) and summary information on product stability prior to and during administration (e.g., in-device hold times and temperatures).
— FDA: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)…Draft Guidance for Industry

Our evo system (evo hardware + currently supports the guidance advise relating to shipping condtions, storage conditions expiration date/time, chain of custody,  and handling at the clinical site to the bedside. 

We are proud to have lead the way in the awareness of these needs and to have developed a solution for these needs. Our system is IND ready!

Kymriah® Approved By EC & Novartis Announces New Facility

FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo

FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo



 Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Kymriah   developed in collaboration with the University of Pennsylvania (Penn)   is a ground-breaking one-time treatment that uses a patient's own T cells to fight cancer, and the only chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in the EU for these two distinct B-cell malignancies. Kymriah was also the first CAR-T cell therapy ever approved by the US Food and Drug Administration (FDA)....


With the approval in Europe of its CAR-T cancer drug Kymriah, Novartis figures demand will call for more production. To crank that capacity up, the drugmaker will build a plant in Switzerland that eventually may employ 450 workers.


Fierce Pharma article HERE 

Reuters article HERE 

Press Release HERE




Yescarta® Approved By EC

kite pharma.png

Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. The Marketing Authorization approves axicabtagene ciloleucel for use in the 28 countries of the European Union, Norway, Iceland and Liechtenstein.


Read Press Release HERE

See You In Boston!

boston biotech week.jpg

We will be at two, yes two, conferences in Boston, September 4-7 as part of Boston Biotech Week.

CAR TCR Boston logo.jpg

We will be at Booth: #22


Seaport Hotel & World Trade Center
One Seaport Lane, Boston
MA 02210

Conference Info: Here

cell and gene commercialization.jpg

We will be at Booth: #2064


Hynes Convention Center,
Boston, MA

Conference Info: Here

Bruce McCormick, President of Savsu, will be speaking at this event on Friday September 7, 9:00-9:30AM in the "Logistics, Supply Chain, and Cryopreservation" track.

Topic of talk is "Experience From The Field: Maintaining a Two Temperature Cold Chain For Regenerative Medicine".   Link to program is HERE

bruce talk.jpg

We have a new home! can't visit yet.



We have secured a fantastic new location for Savsu's Design and Technology Center in Albuquerque! 

New Address:   4209 Balloon Park Rd. NE, Albuquerque, NM 87109

The 10,000 sf building will house an expanded design and prototyping facility with new robotic and CNC machinery, our growing customer service group, an expanded warehouse and fulfillment group, high speed data center, and new training facility.  Our new Albuquerque home is the latest in our growing, distributed network of business centers: software dev (Seattle, Washington), component assembly (Leon, Mexico), and business services (Old Bethpage, NY).

We can't wait for you to visit but....we're not quite ready yet!   The building is being completely remodeled for us right now.   We will begin moving machinery and equipment in late August.  Target move-in completion is mid September. 

We are so excited about our new place we issued a press release to let everyone know: read it HERE

We look forward to showing you around our new home!

(Oh!  Just got a nice article about our expansion in the Albuquerque Business Journal:  you can read it HERE)